Progen gets strategic advice
Wednesday, 27 August, 2008
Progen Pharmaceuticals [ASX: PGL] has appointed a new group of corporate advisors to help guide the company's development.
The company has commissioned the services of the independent corporate advisory firm Beerworth and Partners (BPL).
BPL has been hired to assess Progen's operations and develop strategic options to be reviewed by Progen's Board of directors.
The advisory firm will also provide general corporate advice and assist the board as required.
According to Progen, the decision to hire advisors was made when the directors realised the company's strong cash position after terminating the PI88 Phase III Pathway study in liver cancer.
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
